Telehealth Is Fastest Growing Segment Fueling The Growth Of The Global Remicade Biosimilars Market

Lucy Kart

Telehealth Is Fastest Growing Segment Fueling The Growth Of The Global Remicade Biosimilars Market

Remicade biosimilars are a therapeutic equivalent of reference biologics which provide similar clinical efficacy and safety profile as of reference drug with more affordable treatment options. With government support for cost-effective treatment alternatives and gradual patent expiry of reference biologics, biosimilars are increasingly adopted.

The global Remicade biosimilars Market is estimated to be valued at US$ 3,007.28 Mn in 2023 and is expected to exhibit a CAGR of 35% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the major trends gaining traction in the remicade biosimilars market is growing adoption of telehealth. Telehealth helps bridge the gap between patients and healthcare providers in remote areas by offering virtual medical consultation and remote patient monitoring services. During COVID-19 pandemic, telehealth played a pivotal role in delivering continuous care while maintaining social distancing. Its ability to improve access to treatments at lower costs is boosting the demand for cost-effective drugs like remicade biosimilars. This trend is expected to continue in the forecast period with increasing digital healthcare adoption.

Segment Analysis

The global Remicade biosimilars market is dominated by rheumatoid arthritis segment. Rheumatoid arthritis is the largest indication treated with Remicade. It is an autoimmune disease where the immune system attacks the joints, causing swelling and pain. Since Remicade biosimilars work by suppressing the immune system, they are highly effective in treating rheumatoid arthritis. Other major segments include crohn's disease, ulcerative colitis and psoriasis.

Key Takeaways

Global Remicade Biosimilars Market Demand is expected to witness high growth, exhibiting CAGR of 35% over the forecast period, due to increasing prevalence of immune system related diseases and cost advantages of biosimilars over reference biologics.

North America is expected to dominate the global Remicade biosimilars market over the forecast period. This is attributed to the presence of major product manufacturers and rapid adoption of cost effective biosimilars in the region. Europe is also expected to hold significant market share owing to supportive regulatory policies for biosimilars in countries like UK, Germany, France and Italy. Asia Pacific is anticipated to exhibit fastest growth rate owing to rising healthcare investments, growing incidences of immune disorders and increasing awareness about biosimilars.

Key players operating in the Remicade biosimilars market are Janssen Biotech Inc., Merck &Co., Pfizer Inc., Celltrion Inc., Alvogen, Napp Pharmaceuticals, and Nippon Kayaku. Janssen Biotech Inc. currently dominates the market with its reference product Remicade. Celltrion Inc. is a leading player in market with its Remicade biosimilar 'Remsima'. Pfizer Inc. is also a major player with its Remicade biosimilar 'Inflectra'.

Get More Insights on this Report- https://www.rapidwebwire.com/remicade-biosimilars-market-future-trends-growth-and-forecast/

Lucy Kart

Sneha 2024-01-18

The global Remicade Biosimilars Market is estimated to be valued at US$ 3007 million in 2023 and is expected to exhibit a CAGR of 3. As the first Remicade biosimilars reach the market, they capture market share from the originator drug. Key TakeawaysThe Global Remicade Biosimilars Market Size is expected to witness high growth over the next decade. Key players in the Remicade biosimilars market operating include Celltrion, Samsung Bioepis,Biogen,Dr. Reddy's Laboratories also markets Remicade biosimilars and aim to grow their market presence over coming years.

The Global Remicade Biosimilars Market Growth Accelerated By Increase In Research And Development

ashwini bakhade 2024-02-02

The global Remicade biosimilars Market is estimated to be valued at US$ 3464. Segment AnalysisThe global Remicade Biosimilars market is dominated by the rheumatoid arthritis sub-segment owing to the extensive prevalence of the disease. The global Remicade biosimilars Market is estimated to be valued at US$ 3464. Regional analysis comprisesNorth America currently dominates the global Remicade Biosimilars market due to the presence of developed healthcare infrastructure and high awareness regarding biosimilars. Key players related content comprisesKey players operating in the Remicade Biosimilars market are Henkel AG & Co.

Navigating the Remicade Biosimilars Market: Strategies and Opportunities

Roger 2023-11-06

Fortunately, the emergence of Remicade biosimilars Market has introduced competition and the potential for more accessible and cost-effective treatment options. Understanding Remicade and Biosimilars:Remicade, also known as infliximab, is a biologic drug designed to target tumor necrosis factor-alpha (TNF-alpha), a key player in inflammatory responses. Benefits of Remicade Biosimilars:Cost Reduction: The primary advantage of Remicade biosimilars is their potential to significantly lower the cost of treatment. Conclusion:The emergence of Remicade biosimilars in the market is a promising development for patients with autoimmune disorders who rely on biologic therapies. As the Remicade Biosimilars Market Size continues to expand, patients and healthcare providers can look forward to a more accessible, affordable, and patient-centered approach to managing autoimmune diseases.

The Rise of Remicade Biosimilars in Chronic Disease Treatment

Purvaja 2024-02-14

This article discusses Remicade biosimilars and their role in making biologic therapy more accessible and affordable. Some of the key Remicade biosimilars approved so far are: - Inflectra (infliximab-dyyb): Approved by EMA in 2013 and FDA in 2016, manufactured by Celltrion. All these products demonstrate biosimilarity to Remicade and provide safe and effective treatment alternatives for conditions where Remicade is indicated. The cost savings from biosimilars are helping to make biologic treatment more sustainable for healthcare systems. Substituting Remicade with biosimilars could potentially save billions annually for the US healthcare system.

Sumedha 2024-01-23

The global biosimilars market is estimated to be valued at US$ 29. 9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Key Takeaways The Global Biosimilars Market Share is expected to witness high growth over the forecast period of 2023-2030. Favorable regulatory guidelines and rising healthcare spending will accelerate biosimilars market growth in Asia Pacific region during the forecast period. Key players - Key players operating in the biosimilars market include U.

Pooja salve 2023-08-14

The global Biosimilars market is estimated to be valued at USD 29. They offer a cost-effective alternative to expensive biologic drugs, making them more accessible to patients globally. Patent Expiry of Biologic Drugs: Many biologic drugs have reached or are nearing their patent expiration, creating opportunities for biosimilar manufacturers. Increasing Demand: The rising prevalence of chronic diseases and the need for cost-effective treatment options drive the demand for biosimilars. Intellectual Property Rights: Risks associated with intellectual property infringement may hamper the growth of the biosimilars market.

WHO TO FOLLOW

MORE FROM AUTHOR

Open source CRM software: Short Summary

Lucy Kart 2024-03-26

Next Generation Probiotics: Rising Significance of Health and Wellness

Lucy Kart 2024-03-22

Shavers - An Essential Grooming Tool

Lucy Kart 2024-03-22

The Rapid Rise of Europe E-bikes

Lucy Kart 2024-03-20

Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.

Press enter to search

saikiran TBRC 2024-03-02

Learn More On The Remicade Biosimilar Market:https://www. The remicade biosimilar market size is expected to see exponential growth in the next few years. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence. The rise in the incidence of autoimmune diseases is expected to propel the growth of the remicade biosimilar market going forward. Major companies operating in the Remicade biosimilar market are developing innovative products to sustain their position in the market.

Biswadeep 2022-05-10

The Biosimilars Global Market Report 2021-31 by The Business Research Company describes and explains the global biosimilars market and covers 2016 to 2021, termed the historic period, and 2022 to 2026, termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region. id=2807&type=smp Biosimilars Global Market Report 2022 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.

Jignesh Jariwala 2022-09-21

has added a new report titled, ‘Biosimilars Market - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecasts, 2022 - 2026’ to its vast repository of research reports. The global Biosimilars market was estimated at USD 15. The report also describes the market dynamics, including growth drivers, restraints, challenges, threats, and potential growth opportunities in the global market and its sub-markets. id=40This report categorizes the biosimilars market into the following segments and subsegments:Biosimilars Market, by Product· Monoclonal Antibodieso Infliximabo Trastuzumabo Rituximabo Adalimumabo Other monoclonal antibodies (bevacizumab, cetuximab, ranibizumab, denosumab, and eculizumab)· Insulin· Granulocyte Colony-Stimulating Factor· Erythropoietin· Recombinant Human Growth Hormone· Etanercept· Follitropin· Teriparatide· Interferons· Enoxaparin Sodium· Glucagon· CalcitoninBiosimilars Market, by Indication· Oncology· Inflammatory & Autoimmune Disorders· Chronic Diseases· Blood Disorders· Growth Hormone Deficiency· Infectious Diseases· Other Indications (infertility, hypoglycemia, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases)Some of the key geographies mentioned in this report include:· North America (U. S and Canada and rest of North America)· Europe (Germany, France, Italy, and Rest of Europe)· Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific)· LAMEA (Brazil, Turkey, Saudi Arabia, South Africa, and Rest of LAMEA)Key questions answered in the report· What will be the market size and growth rate by the end of the forecast period?

Varisha Kausar 2021-11-30

The Biosimilars Market Report, in its latest update, highlights the significant impacts and the recent strategical changes under the present socio-economic scenario. Get | Download FREE Sample Report of Global Biosimilars Market @ https://www. The report covers the complete competitive landscape of the Worldwide Biosimilars market with company profiles of key players such as:Hospira, Inc. Which application and type segment holds the maximum share in the Global Biosimilars market? Purchase the Complete Global Biosimilars Market Research Report @ https://www.

Aafiya.Khanam 2021-11-17

The newly added Remicade Biosimilar Market research report by Value Market Research disclose all the important information associated with the market such as value, growth factor, trends, market share, size, and challenges for the forecasted timeline 2020-2027. The report also covers detailed competitive landscape including company profiles of key players operating in the global market. Get more information on "Global Remicade Biosimilar Market Research Report" by requesting FREE Sample Copy athttps://www. Browse Global RemicadeBiosimilar Market Research Report with detailed TOC athttps://www. By Disease Indication· Ulcerative Colitis· Rheumatoid Arthritis· Ankylosing Spondylitis· Crohn’s Disease· Psoriatic Arthritis· Plaque PsoriasisRegional AnalysisFurthermore, the report comprises of the geographical segmentation, which mainly focuses on current and forecast demand for remicadebiosimilar in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Saya Bonde 2023-06-28

(110+ Pages) The Latest Biosimilars Market (2023-2030) Research Report predicts significant growth in the worldwide market. The report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, geographical expansions and technological innovations in the market. Also, the report includes comprehensive analysis on market conditions, growth factors, and competition in the Biosimilars Market. com/insight/request-sample/750List of TOP Competitors in Market Report are:Novartis AG, Pfizer, Inc. ➜ Examination of the regulatory and policy changes affecting the Biosimilars market and the implications of these changes for market participants.

nilesh 2022-02-01

about the global biosimilars market that predicts massive enlargement for this market with 26% CAGR during the forecast period between 2016 and 2023. com/sample_request/1329 Key Players The key players in the global biosimilars market include Accord Healthcare (UK), Amgen Inc. The segmentation global biosimilars market is on the basis of application, manufacturing, product, and region. Latest Industry News• Mundipharma, a network of independent pharma companies, has acquired Spanish biosimilars development company Cinfa Biotech. 10 OCT 2018• The new white paper issued by the Association of European Cancer Leagues, a nonprofit, pan-European organization of national and regional cancer societies, has called for the greater use of biosimilars as a means to increase patient access to cancer treatment, and reduce costs.

john clinton 2022-09-15

90%CAGR over the forecast period from 2022 to 2030, according to the latest research report from Market Research Future (MRFR). This is also likely to remain a key driver for the global biosimilars market over the forecast period. com/sample_request/1329Biosimilars Market Segmentation:The global biosimilars market is segmented on the basis of product, application, end user, and region. By product type, the global biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. com/reports/biosimilars-market-1329 About Market Research Future:At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.

Uday Kiran 2024-03-01

Learn More On The Biosimilars Market:https://www. The biosimilars market size is expected to see rapid growth in the next few years. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market. Key Mergers And Acquisitions In Biosimilars Market 35. AppendixTop Major Players :· Becton Dickinson and Company (BD)· Hologic, Inc.

Ulcerative Colitis Market Size, Share, Growth, Analysis, Trend, and Forecast Research Report by 2030

jhon tanison 2022-11-16

It is an investigative study covering analysis of market drivers, restraints, challenges, threats, and growth prospects in the global Ulcerative Colitis market. The global Ulcerative Colitis market report is a methodical research of the Ulcerative Colitis market done by extensive primary and secondary research. The fundamental purpose of the Ulcerative Colitis market report is to offer an accurate and strategic analysis of the Ulcerative Colitis business sphere. The market research report aims to offer accurate and strategic analysis of the Ulcerative Colitis business sphere. com

Monoclonal Antibodies Market Size, Growth, Share, Trends and Forecast 2022-2027

fairfieldmarketresearch 2022-06-23

The current success of monoclonal antibody therapy and its promising future potential are expected to create extremely viable business opportunities in the global monoclonal antibodies market over the forecast period. Additionally, several clinical trials are in their later stages, setting the stage for significant expansion of the monoclonal antibodies market. Get a Sample Copy of Monoclonal Antibodies Market:https://www. Over the forecast period, these factors are forecasted to positively influence the expansion of the global monoclonal antibodies market. Leading Market PlayersSome of the key players in the global monoclonal antibodies market include F Hoffmann-La Roche AG, Novartis AG, Amgen Inc.

Advancements in Monoclonal Antibodies: Pioneering Therapeutic Innovations

harries jackson 2023-06-23

Introduction: Technological advancements have propelled the field of monoclonal antibodies, enabling the development of novel therapeutics with enhanced efficacy and precision. In this blog, we will explore the latest technological innovations in monoclonal antibodies. They can redirect immune cells to tumor cells, Monoclonal Antibodies Market enhance immune responses, and target multiple disease pathways simultaneously. Oncology: Monoclonal antibodies have revolutionized cancer treatment by targeting specific molecules or receptors on cancer cells. In this blog, we will introduce the monoclonal antibodies market, exploring its significance, growth factors, and potential applications.

nilesh 2021-11-17

com/sample_request/1329 Global Biosimilars Market –Major Key PlayersPfizer Inc. Teva Pharmaceutical share around 20 % of total global biosimilars market. This company shares 11 % of total global biosimilars market. com/reports/biosimilars-market-1329 About Market Research Future:At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Steve martin 2023-06-26

Developed through a rigorous scientific process, Biosimilars are highly similar copies of already approved biologic drugs, known as the reference products. Firstly, it increases patient access to biologic medicines by offering more affordable options. This not only improves patients' quality of life but also reduces the financial burden on healthcare systems and insurance providers. Overall, Biosimilars represent a significant step forward in improving patient access to biologic medicines. By offering cost-effective alternatives, biosimilars have the potential to transform healthcare and ensure that more patients can benefit from these life-changing therapies.